Ye Xiaofeng
Known title: CFOCIK: 0002136887
Associated companies
Transaction History
| ANL | ▼ Sell | Open Market | 5,667 | $81K | 8/26/2026 | View on chart |
| ANL | ▼ Sell | Open Market | 6,000 | $84K | 8/24/2026 | View on chart |
| ANL | ▼ Sell | Open Market | 5,667 | $81K | 8/26/2026 | View on chart |
| ANL | ▼ Sell | Open Market | 6,000 | $84K | 8/24/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Adlai Nortye Partners with Lilly and Merck for AN4035 Trials
Adlai Nortye has entered clinical collaboration agreements with Eli Lilly and Merck KGaA to evaluate combining its AN4035 drug with Cetuximab. This partnership provides access to the ERBITUX antibody for upcoming trials. The stock has recently rallied significantly, moving from a 52-week low of $0.88 to a high of $17.25.
Adlai Nortye Partners with Lilly and Merck for AN4035 Trials. Adlai Nortye has entered clinical collaboration agreements with Eli Lilly and Merck KGaA to evaluate combining its AN4035 drug with Cetuximab. This partnership provides access to the ERBITUX antibody for upcoming trials. The stock has recently rallied significantly, moving from a 52-week low of $0.88 to a high of $17.25.